Seventh Generation vs Johnson & Johnson
Side-by-side comparison of AI visibility scores, market position, and capabilities
Unilever-owned natural cleaning brand with transparent ingredient disclosure; plant-based formulations and packaging transparency competing with Method and Mrs. Meyer's in natural cleaning market.
About
Seventh Generation is a Vermont-based natural cleaning products and personal care brand known for plant-based, non-toxic formulations and transparent ingredient disclosure — producing laundry detergent, dish soap, household cleaners, baby products, and feminine care products that avoid synthetic fragrances, dyes, and petroleum-derived chemicals. Founded in 1988 by Jeffrey Hollender and Alan Newman in Burlington, Vermont, Seventh Generation was acquired by Unilever in 2016 for approximately $600 million, bringing the brand into Unilever's sustainable living brand portfolio alongside Ben & Jerry's and The Body Shop.\n\nSeventh Generation's product philosophy centers on transparency ("Comes Clean" ingredient disclosure, listing all ingredients on packaging), plant-based formulations, and environmental footprint reduction (products made with recycled content packaging, concentrated formulas to reduce shipping weight). The brand's name is inspired by the Great Law of the Iroquois, which encourages considering the impact of decisions on the seventh generation ahead — embedding environmental philosophy into brand identity.\n\nIn 2025, Seventh Generation operates within Unilever's Health and Wellbeing division, competing with Method (SC Johnson), Mrs. Meyer's Clean Day (SC Johnson), Ecover, and Eco Nuts for the natural cleaning products market. The natural cleaning segment has grown as mainstream consumers shift away from conventional cleaners with synthetic ingredients, and as the natural products category has moved from specialty health food stores to mainstream supermarkets. The brand competes for shelf space at Target, Whole Foods, and online against Seventh Generation's siblings in Unilever's portfolio. The 2025 strategy focuses on expanding plant-based formulation innovation, growing online direct sales, and deepening the brand's environmental activism credentials to differentiate from conventional brands adding "green" claims.
FY2024 Sales: $88.8B (+4.3%) | Net Profit: $14.1B (+5.6%) | EPS: $5.79 | Adjusted EPS: $9.98 | FY2025 Guidance: Operational Sales Growth 2.5-3.5%, Adj EPS $10.75-$10.95 (+8.7% midpoint)
About
Johnson & Johnson is one of the world's largest healthcare companies, founded in 1886 by brothers Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson in New Brunswick, New Jersey, where the company remains headquartered. Established to manufacture ready-to-use surgical dressings at a time when post-operative infection was a leading cause of surgical mortality, J&J was built on the scientific principles of antiseptic surgery advocated by Joseph Lister. The company trades on the NYSE under ticker JNJ and has evolved over 135+ years from a consumer health products manufacturer into a focused MedTech and pharmaceutical enterprise, completing the spinoff of its consumer health segment (Kenvue) in 2023.\n\nJohnson & Johnson now operates through two segments: Innovative Medicine and MedTech. Innovative Medicine encompasses oncology, immunology, neuroscience, infectious disease, and cardiovascular pharmaceutical products — including blockbusters Darzalex, Stelara, Tremfya, and Rybrevant. The MedTech segment includes surgical robotics (Ottava platform in development), electrophysiology (Abiomed, Biosense Webster), orthopedics (DePuy Synthes), and surgery systems, serving hospitals and surgical centers worldwide. Following the Kenvue separation, J&J is a pure-play healthcare technology and pharmaceutical company with significantly higher growth and margin profiles than its historical blended consumer-pharma-medtech structure.\n\nJohnson & Johnson reported FY2024 sales of $88.8 billion, up 4.3% year over year, with net profit of $14.1 billion, up 5.6%. The company's Innovative Medicine segment continues to grow driven by oncology and immunology portfolio strength, while MedTech benefits from procedure volume recovery and robotic surgery adoption. J&J's scale, R&D pipeline depth, and global commercial infrastructure — spanning more than 60 countries — position it as one of the two or three most consequential healthcare enterprises globally, with a patent portfolio, clinical trial network, and regulatory expertise that are nearly impossible to replicate.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.